US6967016B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of determining therapeutic activity and/or possible side-effects of a medicament
Assignee: Primagen BV
•
Filing: 2001-12-04
•
Granted: 2005-11-22
•
Expires: 2021-12-04
Abstract
Abstract The invention relates to the diagnosis of disease or the determination of functioning of cellular organisms, being of multi-cellular or unicellular nature, being visible by the naked eye or being a microorganism. The invention provides a method for determining functioning of a cellular organism comprising determining the relative ratio of a first endosymbiont cellular organelle nucleic acid and/or gene product thereof in a sample obtained from the organism in relation to the amount of a second nucleic acid and/or gene product thereof.
Inventors
- 👤 Bob Van Gemen
- 👤 Eveline Catherina A. C. Timmermans
- 👤 Anthonij de Ronde
- 👤 Irene Johanna M. Dobbelaer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:41
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6876; C12Q1/6888; C12Q1/6809; C12Q2600/00; C12Q2600/136; C12Q2600/158; C12Q2600/16
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
87 words
A method of determining whether a medicament has therapeutic activity and/or possible side-effects, said method comprising: introducing a medicament to an organism; determining in a sample obtained from said organism a relative ratio of a mitochondrial nucleic acid and/or gene product thereof to a chromosomal nucleic acid and/or gene product thereof; and determining whether there is a change in the relative ratio during and/or after introduction of the medicament, wherein said change in said relative ratio is indicative that said medicament has therapeutic activity and/or possible side-effects.
Claim 2
Independent Claim
87 words
A method of determining whether a medicament has therapeutic activity and/or possible side-effects, said method comprising: introducing a medicament to an organism; determining in a sample obtained from said organism a relative ratio of a mitochondrial nucleic acid and/or gene product thereof to a chromosomal nucleic acid and/or gene product thereof; and determining whether there is a change in the relative ratio during and/or after introduction of the medicament, wherein said change in said relative ratio is indicative that said medicament has therapeutic activity and/or possible side-effects.
Claim 3
Dependent Claim
24 words
The method according to claim 1 , wherein said introducing said medicament comprises introducing said medicament to said organism for at least three months.
Claim 4
Dependent Claim
18 words
The method according to claim 1 , wherein said medicament is used for treatment of a chronic disease.
Claim 5
Dependent Claim
33 words
The method according to claim 1 , wherein said introducing said medicament comprises introducing said medicament to an organism free from side-effects at a first time said medicament is introduced to said organism.
Claim 6
Dependent Claim
23 words
The method according to claim 1 , wherein said therapeutic activity comprises a therapeutic activity against an HIV-related disease and/or a tumor-related disease.
Claim 7
Dependent Claim
16 words
The method according to claim 1 , wherein said medicament comprises a nucleoside and/or nucleotide analogue.
Claim 8
Dependent Claim
29 words
The method according to claim 6 , wherein said nucleoside and/or nucleotide analogue is selected from the group consisting of fludarabine, mercaptopurine, tioguanine, cytarabine, flurouracil, gemcyatbine, and mixtures thereof.
Claim 9
Dependent Claim
18 words
The method according to claim 1 , wherein said medicament comprises AZT, ddI, ddC, d4T, 3TC or tenofofir.
Claim 10
Dependent Claim
24 words
The method according to claim 1 , wherein said determining said ralative ratio comprises determining said relative ratio prior to said introducing said medicament.
Claim 11
Dependent Claim
35 words
The method according to claim 1 , wherein said relative ratio of said mitochondrial nucleic acid and/or gene product thereof to said chromosomal nucleic acid and/or gene product thereof is determined in a single assay.
Claim 12
Dependent Claim
31 words
The method according to claim 10 , further comprising amplifying said mitochondrial nucleic acid and/or gene product thereof and said chromosomal nucleic acid and/or gene product thereof in a single assay.
Claim 13
Dependent Claim
37 words
The method according to claim 10 , wherein said relative ratio is determined directly by dividing an amount of said mitochondrial nucleic acid and/or gene product by an amount of said chromosomal nucleic acid and/or gene product.
Claim 14
Dependent Claim
37 words
The method according to claim 10 , wherein said relative ratio is determined directly by dividing an amount of said chromosomal nucleic acid and/or gene product by an amount of said mitochondrial nucleic acid and/or gene product.
Claim 15
Dependent Claim
22 words
The method according to claim 10 , wherein said relative ratio is determine by comparing said relative ratio to a reference curve.
Claim 16
Dependent Claim
38 words
The method according to claim 10 , wherein said mitochondrial nucleic acid and/or gene product thereof and said chromosomal nucleic acid and/or gene product thereof are obtained from a peripheral blood mononuclear cell or fibroblast of said organism.
References Cited (Backward Citations)
US5569754A
Cited
WO1996006191A2
Cited
WO1997039149A1
Cited
WO1998017826A1
Cited
US6232065B1
Cited
WO1999066075A2
Cited
US6221600B1
Cited
US20020049176A1
Cited
US20030003488A1
Cited
US20020048763A1
Cited
US20020169562A1
Cited
US20030099933A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2008-11-21 | 2009-05-23 | 2009-11-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2012-11-21 | 2013-05-23 | 2013-11-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2016-11-21 | 2017-05-23 | 2017-11-22 | $7700.00 | Window Closed / Lapsed |